Market revenue in 2020 | USD 48,796.9 million |
Market revenue in 2028 | USD 173,550.2 million |
Growth rate | 17.2% (CAGR from 2020 to 2028) |
Largest segment | (crispr)/cas9 |
Fastest growing segment | Meganuclease |
Historical data covered | 2017 - 2019 |
Base year for estimation | 2020 |
Forecast period covered | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
Key market players worldwide | Thermo Fisher Scientific Inc, Takara Bio Inc, Danaher Corp, Promega, GenScript ProBio, New England Biolabs, Applied Materials Inc, Bio-Rad Laboratories Inc, Lucigen, Synthego, Addgene, Abcam PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mutation detection kits in genome editing market will help companies and investors design strategic landscapes.
(crispr)/cas9 was the largest segment with a revenue share of 42.99% in 2020. Horizon Databook has segmented the North America mutation detection kits in genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2017 to 2028.
High investments in R&D, continuous technological developments by key players, availability of technologically advanced healthcare infrastructure, and a strong regional economy have resulted in North America’s current dominance in the global market. In addition, local presence of key operating players in the region can further strengthen regional revenue generation.
GeneScript, Thermo Fisher Scientific, Takara Bio USA are some prominent players operating in North America. Furthermore, government initiatives in the U.S. and Canada are supporting research in therapeutic development in oncology space.
For instance, the Personalized Onco-Genomics program of the BC Cancer utilizes whole-genome and transcriptome analysis for the determination of cancer genes and identification of corresponding drugs that may inhibit relevant pathways in cancer-affected patients.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America mutation detection kits in genome editing market , including forecasts for subscribers. This continent databook contains high-level insights into North America mutation detection kits in genome editing market from 2017 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account